XOMA Corporation (Nasdaq: XOMA) is a biotech enterprise capitalizing on its antibody legacy in a new way.

With over 35 years of discovery activity, XOMA currently has more than 20 partnered and fully-funded programs with the potential to drive milestone and royalty payments, along with multiple additional programs ready for out-licensing.  XOMA’s business strategy is to grow shareholder value by combining the revenue streams derived from this existing portfolio with future newly acquired milestone and royalty revenues while adopting an extremely lean cost infrastructure, to deliver growing cash flow and profits.

XOMA has engaged in multiple and productive licensing agreements and development collaborations related to its antibody technologies. Examples where XOMA’s technologies have contributed to the success of marketed antibody products include LUCENTIS ® (ranibizumab injection) for wet age-related macular degeneration, CIMZIA ® (certolizumab pegol) for rheumatoid arthritis and Crohn’s disease, and Rituxan (rituximab) indicated for the treatment of certain types of non-Hodgkin’s lymphoma. The company has sold its rights to receive milestones and royalties on product sales related to these products.